Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50
HOS-112180 · Präparat HOS-093615
If genotyping is not feasible,
full monitoring of safety and
efficacy should be performed.
Fluconazole 200 mg once Atazanavir and fluconazole concentrations No dosage adjustments are
daily were not significantly modified when needed for fluconazole and
(atazanavir 300 mg and REYATAZ/ritonavir was co-administered REYATAZ.
ritonavir 100 mg once daily) with fluconazole.
ANTIMYCOBACTERIAL
Rifabutin 150 mg twice Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ,
weekly Rifabutin Cmax: ↑149% (↑103% ↑206%)** the recommended dose of
(atazanavir 300 mg and Rifabutin Cmin: ↑40% (↑5% ↑87%)** rifabutin is 150 mg 3 times per
ritonavir 100 mg once daily) week on set days (for example
25-O-desacetyl-rifabutin AUC: ↑990% Monday-Wednesday-Friday).
(↑714% ↑1 361%)** Increased monitoring for
25-O-desacetyl-rifabutin Cmax: ↑677% rifabutin-associated adverse
(↑513% ↑883%)** reactions including neutropenia
25-O-desacetyl-rifabutin Cmin: ↑1 045% and uveitis is warranted due to
(↑715% ↑1 510%)** an expected increase in
exposure to rifabutin. Further
**When compared to rifabutin 150 mg dosage reduction of rifabutin to
once daily alone. Total rifabutin and 150 mg twice weekly on set
25-O-desacetyl-rifabutin AUC: ↑119% days is recommended for
(↑78% ↑169%). patients in whom the 150 mg
dose 3 times per week is not
In previous studies, the pharmacokinetics tolerated. It should be kept in
of atazanavir was not altered by rifabutin. mind that the twice weekly
dosage of 150 mg may not
provide an optimal exposure to
rifabutin thus leading to a risk
of rifamycin resistance and a
treatment failure. No dose
adjustment is needed for
REYATAZ.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) fluconazole (HOS-087945) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8636d5f40f2d59b4431c4b6441a822c9757fee6002c3bac44d10a6c85c5838ba · Zeichen 27032–30282 im Abschnitt
Wechselwirkungen · Lysodren
Lysodren 500 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-112484 · Präparat HOS-093689
Substances metabolised through cytochrome P450: Mitotane has been shown to have an inductive
effect on cytochrome P450 enzymes. Therefore, the plasma concentrations of the substances
metabolised via cytochrome P450 may be modified. In the absence of information on the specific
P450 isoenzymes involved, caution should be taken when co-prescribing active substances
metabolised by this route such as, among others, anticonvulsants, rifabutin, rifampicin, griseofulvin
and St. John’s wort (Hypericum perforatum). Particularly, mitotane has been shown to have an
inductive effect on cytochrome 3A4. Therefore, the plasma concentrations of the substances
metabolised via cytochrome 3A4 may be modified. Caution should be taken when co-prescribing
active substances metabolised by this pathway such as, among others, sunitinib, etoposide and
midazolam and dose should be adjusted as appropriate when coadministered with mitotane.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) etoposide (HOS-086021) sunitinib (HOS-109453) griseofulvin (HOS-091156) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-11T11:11:00Z · SHA-256 8857f8543d9dfcf9df89b956cb88735a9c924712c239c2879d16e7b6e36c86ba · Passage 33ffffa577eb2424a7b8528ae3d95c1068738efbcf5b41830673b01453bc3bf5 · Zeichen 546–1471 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 6
HOS-114228 · Präparat HOS-094063
Effects of other medicinal products on posaconazole
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for
p-glycoprotein (P-gp) efflux in vitro. Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine,
clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.)
of these clearance pathways may increase or decrease posaconazole plasma concentrations,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) quinidine (HOS-085593) clarithromycin (HOS-084517) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 6f60842686a713ccc539d7c14f2c0f2f1d568475a839e8d698fd3b2d72e03d98 · Zeichen 0–457 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 6
HOS-114230 · Präparat HOS-094063
Rifabutin
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area
under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be
avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of
posaconazole on rifabutin plasma levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage d9f53a887c97318afb483c58023d1fcfb9a8c4477b1695d5c691c5b066f47a30 · Zeichen 699–1130 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 8
HOS-114245 · Präparat HOS-094063
Rifabutin
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. Concomitant
use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the
risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). If these
medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions
related to increased rifabutin levels (e.g. uveitis) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 560a3115909e5c7983f963df77e77a93c933d01c938a27370aa14aea528a5aeb · Zeichen 7916–8392 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-114280 · Präparat HOS-094063
Effects of other medicinal products on posaconazole
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for
p-glycoprotein (P-gp) efflux in vitro. Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine,
clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.)
of these clearance pathways may increase or decrease posaconazole plasma concentrations,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) quinidine (HOS-085593) clarithromycin (HOS-084517) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 6f60842686a713ccc539d7c14f2c0f2f1d568475a839e8d698fd3b2d72e03d98 · Zeichen 0–457 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-114282 · Präparat HOS-094063
Rifabutin
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area
under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be
avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of
posaconazole on rifabutin plasma levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage d9f53a887c97318afb483c58023d1fcfb9a8c4477b1695d5c691c5b066f47a30 · Zeichen 699–1130 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-114296 · Präparat HOS-094063
Rifabutin
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. Concomitant
use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the
risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). If these
medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions
related to increased rifabutin levels (e.g. uveitis) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 560a3115909e5c7983f963df77e77a93c933d01c938a27370aa14aea528a5aeb · Zeichen 7392–7868 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 46–47
HOS-114335 · Präparat HOS-094063
46
clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.)
of these clearance pathways may increase or decrease posaconazole plasma concentrations,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) clarithromycin (HOS-084517) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 92a2a669d06fc9cb0efd407b8dd4b14e3c95f58c62eef26fb82bd75fc2ad92da · Zeichen 645–859 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 47
HOS-114337 · Präparat HOS-094063
Rifabutin
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area
under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be
avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of
posaconazole on rifabutin plasma levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage d9f53a887c97318afb483c58023d1fcfb9a8c4477b1695d5c691c5b066f47a30 · Zeichen 1101–1532 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 48
HOS-114348 · Präparat HOS-094063
Rifabutin
After oral administration, posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %,
respectively. Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to
the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of
posaconazole). If these medicinal products are co-administered, careful monitoring of full blood
counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 29f9128c6776977248c537737d387d1bd93566067d8cbe1a750e3833f73f3517 · Zeichen 6829–7332 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 70
HOS-114387 · Präparat HOS-094063
Effects of other medicinal products on posaconazole
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for
p-glycoprotein (P-gp) efflux in vitro. Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine,
clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.)
of these clearance pathways may increase or decrease posaconazole plasma concentrations,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) quinidine (HOS-085593) clarithromycin (HOS-084517) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 6f60842686a713ccc539d7c14f2c0f2f1d568475a839e8d698fd3b2d72e03d98 · Zeichen 0–457 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 70
HOS-114389 · Präparat HOS-094063
Rifabutin
Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area
under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be
avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of
posaconazole on rifabutin plasma levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage d9f53a887c97318afb483c58023d1fcfb9a8c4477b1695d5c691c5b066f47a30 · Zeichen 699–1130 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 72
HOS-114402 · Präparat HOS-094063
Rifabutin
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively. Concomitant
use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the
risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). If these
medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions
related to increased rifabutin levels (e.g. uveitis) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 560a3115909e5c7983f963df77e77a93c933d01c938a27370aa14aea528a5aeb · Zeichen 7391–7867 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-114822 · Präparat HOS-094169
Colchicine is a substrate of
CYP3A4 and P-gp (an intestinal
efflux transporter).
Antibiotics
Clarithromycin 500 mg Clarithromycin Cmax ↔ Whilst the changes in
BID Clarithromycin AUC ↑ 19% clarithromycin parameters are not
Clarithromycin Cmin ↑ 68% considered clinically relevant, the
reduction in the 14-OH
14-OH-clarithromycin Cmax ↓ metabolite AUC should be
97% considered for the treatment of
14-OH-clarithromycin AUC ↓ infections caused by
97% Haemophilus influenzae in which
14-OH-clarithromycin Cmin ↓ the 14-OH metabolite is most
95% active. The increase of tipranavir
Cmin may be clinically relevant.
Tipranavir Cmax ↑ 40% Patients using clarithromycin at
Tipranavir AUC ↑ 66% doses higher than 500 mg twice
Tipranavir Cmin ↑ 100% daily should be carefully
monitored for signs of toxicity of
CYP 3A4 inhibition by clarithromycin and tipranavir. For
tipranavir/r and P-gp (an patients with renal impairment
intestinal efflux transporter) dose reduction of clarithromycin
inhibition by clarithromycin. should be considered (see
clarithromycin and ritonavir
product information).
Rifabutin 150 mg QD Rifabutin Cmax ↑ 70% Dosage reductions of rifabutin by
Rifabutin AUC ↑ 190% at least 75% of the usual
Rifabutin Cmin ↑ 114% 300 mg/day are recommended (ie
150 mg on alternate days, or
25-O-desacetylrifabutin Cmax ↑ three times per week). Patients
3.2 fold receiving rifabutin with Aptivus,
25-O-desacetylrifabutin AUC ↑ co-administered with low dose
21 fold ritonavir, should be closely
25-O-desacetylrifabutin Cmin ↑ monitored for emergence of
7.8 fold adverse events associated with
rifabutin therapy. Further dosage
Inhibition of CYP 3A4 by reduction may be necessary.
tipranavir/r
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): Haemophilus influenzae (HOS-114823) rifabutin (HOS-086262) clarithromycin (HOS-084517) colchicine (HOS-086147) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 9364d701c0760ed3d66d44141af3d15e6dce638279d23ce5ea4706d31c6562cb · Zeichen 22090–25301 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-114824 · Präparat HOS-094169
No clinically significant change
is observed in tipranavir PK
parameters.
Rifampicin Co-administration of protease Concomitant use of Aptivus, co-
inhibitors with rifampicin administered with low dose
substantially decreases protease ritonavir, and rifampicin is
inhibitor concentrations. In the contraindicated (see section 4.3).
case of tipranavir co- Alternate antimycobacterial
administered with low dose agents such as rifabutin should be
ritonavir, concomitant use with considered.
rifampicin is expected to result in
sub-optimal levels of tipranavir
which may lead to loss of
virologic response and possible
resistance to tipranavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262) lead (HOS-085592) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 22c480831bf584b925ad93bcda9cdab953947ff091675429065beb340adfa99a · Zeichen 25327–26353 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 18–19
HOS-116385 · Präparat HOS-094447
18
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not
been shown to cause profound decreases recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development boosted PREZISTA is
(CYP450 enzyme induction). During contraindicated (see section 4.3).
attempts to overcome the decreased
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and
darunavir Cmin ↑ 68% increased monitoring for rifabutin
related adverse events is warranted
darunavir Cmax ↑ 39%
** in patients receiving the
sum of active moieties of rifabutin (parent
combination with PREZISTA
drug + 25-O-desacetyl metabolite)
co-administered with ritonavir. In
case of safety issues, a further
The interaction trial showed a
increase of the dosing interval for
comparable daily systemic exposure for
rifabutin and/or monitoring of
rifabutin between treatment at 300 mg
rifabutin levels should be
once daily alone and 150 mg once every
considered.
other day in combination with
Consideration should be given to
PREZISTA/ritonavir (600/100 mg twice
official guidance on the
daily) with an about 10-fold increase in
appropriate treatment of
the daily exposure to the active
tuberculosis in HIV infected
metabolite 25-O-desacetylrifabutin.
patients.
Furthermore, AUC of the sum of active
Based upon the safety profile of
moieties of rifabutin (parent drug
PREZISTA/ritonavir, the increase
+ 25-O-desacetyl metabolite) was
in darunavir exposure in the
increased 1.6-fold, while Cmax remained presence of rifabutin does not
comparable. warrant a dose adjustment for
Data on comparison with a 150 mg once PREZISTA/ritonavir.
daily reference dose is lacking. Based on pharmacokinetic
modeling, this dosage reduction of
(Rifabutin is an inducer and substrate of 75% is also applicable if patients
CYP3A.) An increase of systemic receive rifabutin at doses other
exposure to darunavir was observed when than 300 mg/day.
PREZISTA co-administered with 100 mg
ritonavir was co-administered with Co-administration of PREZISTA
rifabutin (150 mg once every other day). co-administered with cobicistat
and rifabutin is not recommended.
ANTINEOPLASTICS
Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal
Nilotinib expected to increase these antineoplastic products may be increased when
Vinblastine plasma concentrations. co-administered with boosted
Vincristine (CYP3A inhibition) PREZISTA resulting in the
potential for increased adverse
events usually associated with
these agents.
Caution should be exercised when
combining one of these
antineoplastic agents with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 80d9982d7333f238a9b42ff2871813e3ef61b0aafc430c83e6b17352f5e98202 · Zeichen 44997–51632 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-116525 · Präparat HOS-094447
60
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and
darunavir Cmin ↑ 68% increased monitoring for rifabutin
related adverse events is warranted
darunavir Cmax ↑ 39%
** in patients receiving the
sum of active moieties of rifabutin (parent
combination with PREZISTA
drug + 25-O-desacetyl metabolite)
co-administered with ritonavir. In
case of safety issues, a further
The interaction trial showed a
increase of the dosing interval for
comparable daily systemic exposure for
rifabutin and/or monitoring of
rifabutin between treatment at 300 mg
rifabutin levels should be
once daily alone and 150 mg once every
considered.
other day in combination with
Consideration should be given to
PREZISTA/ritonavir (600/100 mg twice
official guidance on the
daily) with an about 10-fold increase in
appropriate treatment of
the daily exposure to the active
tuberculosis in HIV infected
metabolite 25-O-desacetylrifabutin.
patients.
Furthermore, AUC of the sum of active
Based upon the safety profile of
moieties of rifabutin (parent drug
PREZISTA/ritonavir, the increase
+ 25-O-desacetyl metabolite) was
in darunavir exposure in the
increased 1.6-fold, while Cmax remained presence of rifabutin does not
comparable. warrant a dose adjustment for
Data on comparison with a 150 mg once PREZISTA/ritonavir.
daily reference dose is lacking. Based on pharmacokinetic
modeling, this dosage reduction of
(Rifabutin is an inducer and substrate of 75% is also applicable if patients
CYP3A.) An increase of systemic receive rifabutin at doses other
exposure to darunavir was observed when than 300 mg/day.
PREZISTA co-administered with 100 mg
ritonavir was co-administered with
rifabutin (150 mg once every other day).
ANTINEOPLASTICS
Dasatinib Not studied. PREZISTA is expected to Concentrations of these medicinal
Nilotinib increase these antineoplastic plasma products may be increased when
Vinblastine concentrations. co-administered with PREZISTA
Vincristine (CYP3A inhibition) with low dose ritonavir resulting in
the potential for increased adverse
events usually associated with
these agents.
Caution should be exercised when
combining one of these
antineoplastic agents with
PREZISTA with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) rifabutin (HOS-086262) vinblastine (HOS-086220) vincristine (HOS-086219) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 921968f6843d5fb753e185eb1090f768646fdd146ed0bfdf1dcabbf50411bf6c · Zeichen 36477–41966 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100–101
HOS-116615 · Präparat HOS-094447
100
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not
been shown to cause profound decreases recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development boosted PREZISTA is
(CYP450 enzyme induction). During contraindicated (see section 4.3).
attempts to overcome the decreased
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by
150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of
day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg
darunavir AUC ↑ 53% once every other day) and
darunavir Cmin ↑ 68% increased monitoring for rifabutin
related adverse events is warranted
darunavir Cmax ↑ 39%
** in patients receiving the
sum of active moieties of rifabutin (parent
combination with PREZISTA
drug + 25-O-desacetyl metabolite)
co-administered with ritonavir. In
case of safety issues, a further
The interaction trial showed a
increase of the dosing interval for
comparable daily systemic exposure for
rifabutin and/or monitoring of
rifabutin between treatment at 300 mg
rifabutin levels should be
once daily alone and 150 mg once every
considered.
other day in combination with
Consideration should be given to
PREZISTA/ritonavir (600/100 mg twice
official guidance on the
daily) with an about 10-fold increase in
appropriate treatment of
the daily exposure to the active
tuberculosis in HIV infected
metabolite 25-O-desacetylrifabutin.
patients.
Furthermore, AUC of the sum of active
Based upon the safety profile of
moieties of rifabutin (parent drug
PREZISTA/ritonavir, the increase
+ 25-O-desacetyl metabolite) was
in darunavir exposure in the
increased 1.6-fold, while Cmax remained presence of rifabutin does not
comparable. warrant a dose adjustment for
Data on comparison with a 150 mg once PREZISTA/ritonavir.
daily reference dose is lacking. Based on pharmacokinetic
modeling, this dosage reduction of
(Rifabutin is an inducer and substrate of 75% is also applicable if patients
CYP3A.) An increase of systemic receive rifabutin at doses other
exposure to darunavir was observed when than 300 mg/day.
PREZISTA co-administered with 100 mg
ritonavir was co-administered with Co-administration of PREZISTA
rifabutin (150 mg once every other day). co-administered with cobicistat
and rifabutin is not recommended.
ANTINEOPLASTICS
Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal
Nilotinib expected to increase these antineoplastic products may be increased when
Vinblastine plasma concentrations. co-administered with boosted
Vincristine (CYP3A inhibition) PREZISTA resulting in the
potential for increased adverse
events usually associated with
these agents.
Caution should be exercised when
combining one of these
antineoplastic agents with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e88dcbfcf0dab77e559237cbcfe6847cc43133cb297e06b3715555b2ec19c33c · Zeichen 44468–51104 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116820 · Präparat HOS-094481
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2].
bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable,
enzalutamide, mitotane, or section 4.4]. patients may require an
St. John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, increase the risk of rejection [see and increase tacrolimus dose if
efavirenz, etravirine, section 4.4]. needed [see section 4.2].
nevirapine; weak CYP3A4 Monitor graft function closely.
inducers: flucloxacillin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 9f68b7412442537a87ae5cc4a11a2083ae7ee1d4f84bacfd72b3336085546560 · Zeichen 8467–12012 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.